Partial correction of murine hemophilia A with neo-antigenic murine factor VIII

Human Gene Therapy

Volumn 11, Issue 6, 2000, Pages 881-894

  Sarkar, Rita ^a   Gao, Guang Ping ^b   Chirmule, Narendra ^b   Tazelaar, John ^b   Kazazian Jr , Haig H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; VIRUS VECTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENE THERAPY; HEMOPHILIA A; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION;

ADENOVIRIDAE; ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CYTOTOXICITY, IMMUNOLOGIC; FACTOR VIII; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

ANIMALIA; MURINAE;

EID: 0034630337     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015491     Document Type: Article

References (47)

1. AMANO, K., SARKAR, R., PEMBERTON, S., KEMBALL-COOK, G., KAZAZIAN, H.H., JR., and KAUFMAN, R.J. (1998). The molecular basis for cross-reacting material-positive hemophilia A due to missense mutation within the A2-domain of FVIII. Blood 91, 538.
2. ANTONARAKIS, S.E., and KAZAZIAN, H.H. (1988). The molecular basis of haemophilia A in man. Trends Genet. 4, 233-237.
3. BARR, E., CARROLL, J., KALYNYCH, A.M., TRIPATHY, S.K., KOZARSKY, K., WILSON, J.M., LEIDEN, J.M. (1994). Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther. 1, 51-58.
4. BI, L., LAWLER, A.M., ANTONARAKIS, S.E., HIGH, K.A., GEARHART, J.D., and KAZAZIAN, H.H. JR. (1995). Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genet. 10, 119-121.
5. BI, L., SARKAR, R., NAAS, T., LAWLER, A.M., JAYASHREE, P., SHUMAKER, S.L., BEDIAN, V., and KAZAZIAN, H.H., JR. (1996). Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 88, 3446-3450.
6. CAMPBELL, W.M., SHAPIRO, S.S., WHITEHURST, D., HOYER, L.W., RAO, V., and LAZERSON, J. (1988). The natural history of factor VIII:C inhibitors in patients with haemophilia A: A national cooperative study. II. Observation on the initial development of factor VIII:C inhibitors. Blood 71, 344-348.
7. CAROL, K.K. (1973). Incidence and course of inhibitors among patients with classic haemophilia. Thromb. Diathes. Haemorrh. (Stuttgart) 30, 263.
8. CHEN, H.H., MACK, M.L., KELLY, R., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U.S.A. 94, 1645-1650.
9. CHIRMULE, N., MOSCIONI, A.D., QIAN, G., QIAN, R., and WILSON, J.M. (1998). F as-FasL interactions are critical for immune medialed elimination of transgene expression in the liver. Hum. Gene Ther. 10, 259-269.
10. CHOMCZYNSKI, P., and SACCHI, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156-159.
11. CONNELLY, S., SMITH, T.A.G., DHIR, G., GARDNER, J.M., MEHAFFEY, M.G., ZARET, K.S., McCLELLAND, A., and KALEKO, M. (1995). In-vivo gene delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gene Ther. 6, 185-193.
12. CONNELLY, S., GARDENER, J.M., McCLELLAND, A., and KALEKO, M. (1996a). High level tissue-specific expression of functional human factor VIII in mice. Hum. Gene Ther. 7, 183-195.
13. CONNELLY, S., GARDNER, J.M., LYONS, R.M., McCLELLAND, A., and KALEKO, M. (1996b). Sustained expression of therapeutic levels of human factor VIII in mice. Blood 87, 4671-4677.
14. CONNELLY, S., ANDREWS, J.L., GALLO, A.M., KAYDA, D.B., QIAN, J.-H., HOYER, L., KADAN, M.J., GORZIGLIA, M.I., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91, 3273-3281.
15. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W.W., and SARVETNICK, N. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene. Tolerization of factor IX and vector antigens allows for long term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401-1405.
16. DWARKI, V.J., BELLONI, P., NIJJAR, T., SMITH, J., COUTO, L., RABIER, M., CLIFT, S., BERNS, A., and COHEN, L.K. (1995). Gene therapy for haemophilia A: Production of therapeutic levels of human factor VIII in-vivo in mice. Proc. Natl. Acad. Sci. U.S.A. 92, 1023-1027.
17. ENGELHARDT, J., YANG, Y., STRATFORD-PERRICAUDET, L.D., ALLEN, E.D., KOZARSKY, K., PERRICAUDET, M., YAN, K., JR., and WILSON, J.M. (1993). Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nature Genet. 4, 27-34.
18. EVANS, G.L., and MORGAN, R.A. (1998). Genetic induction of immune tolerance to human clotting factor FVIII in a mouse model for hemophilia A. Proc. Natl. Acad. U.S.A. 95, 5734-5739.
19. 365 of the factor VIII heavy chain. J. Clin. Invest. 82, 123-128.
20. GUIDOTTI, L.G., ISHIKAWA, T., HOBBS, M.V., MATZKE, B., SCHREIBER, R., and CHISARI, F.V. (1996). Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25-36.
21. HOYER, L.W. (1995). Why do so many haemophilia A patients develop an inhibitor? Br. J. Haematol. 90, 498-501.
22. HOYER, L.W., WYSHOCK, E., and COLEMAN, R.W. (1994). Coagulation cofactors V and VIII. In Haemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd Ed. R.W. Coleman, J., Hirch, V.J. Marder, and E.W. Salzman, eds. (J.B. Lippincott, Philadelphia), pp. 109-133.
23. JOHNSON, L.G., BOYLES, S.E., WILSON, J., and BOUCHER, R.C. (1995). Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J. Clin. Invest. 95, 1377-1382.
24. JOOSS, K., TURKA, L.A., and WILSON, J.M. (1998a). Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 5, 309-319.
25. JOOSS, K., YANG, Y., FISHER, K.J., and WILSON, J.M. (1998b). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibres. J. Virol. 72, 4212-4223.
26. KAUFMAN, R.J. (1992). Expression and structure-function properties of recombinant factor VIII. Transfusion Med. Rev. 4, 235-246.
27. KOLLS, J.K., LEI, D., ODOM, G., NELSON, S., SUMMER, W.R., GERBER, M. A., and SHELLITO, J.E. (1996). Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7, 487-497.
28. KOZARSKY, K.F., McKINLEY, D.R., AUSTIN, L.L., RAPER, S.E., STRATFORD-PERRICAUDET, L.D., and WILSON, J.M. (1994). In vivo correction of low density lipoprotein receptor deficiency in the watanabe heritable with recombinant adenoviruses. J. Biol. Chem. 269, 1-8.
29. KOZARSKY, K.F., JOOSS, K., DONAHEE, M., STRAUSS, J.F., and WILSON, J.M. (1996). Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nature Genet. 13, 54-62.
30. LIEBER, A., MARIE-JEANNE, T.F.D., PEETERS, V., MEUSE, L., FAUSTO, N., PERKINS, J., and KAY, M.A. (1995). Adenovirus-mediated urokinase gene transfer induces liver regeneration and allows for efficient retro virus transduction if hepatocytes in vivo. Proc. Natl. Acad. Sci. U.S.A. 92, 6210-6214.
31. LIEBER, A., HE, C.Y., MEUSE, L., SCHOWALTER, D., KIRILLOVA, I., WINTHER, B., and KAY, M.A. (1997). Role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71, 8798-8807.
32. LOLLAR, P., PARKER, E.T., CURTIS, J.E., HELGERSON, S.L., HOYER, L.W., SCOTT, M.E., and SCANDELLA, D. (1994). Inhibition of human factor VIIIa by anti-A2 subunit antibodies. J. Clin. Invest. 93, 2497-2507.
33. MANIATIS, T., FRITSCH, E.F., and SAMBROOK, J. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed., Vol. 3. (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
34. McGINNIS, M.J., KAZAZIAN, H.H., JR., HOYER, L.W., BI, L., INABA, H., and ANTONARAKIS, S.E. (1993). Spectrum of mutations in CRM-positive and CRM-reduced haemophilia A. Genomics 15, 392-398.
35. MONDINO, A., and JENKINS, M.K. (1994). Surface proteins involved in T cell costimulation. J. Leukocyte Biol. 55, 805-815.
36. NEWTON-NASH, D.K., GILL, J.C., FOSTER, P.A., ALEDORT, L.M., HOYER, L.W., LUSHER, J.M., REISNER, H.M., and WHITE, X., II, EDS. (1995). Cellular immune responses to coagulation factor VIII in FVIII inhibitor patients. In Inhibitors to Coagulation Factors. (Plenum Press, New York) p. 285.
37. SCANDELLA, D. (1994). Human antibodies which inactivate factor VIII: Their epitope specificity and biochemical and functional characteristics. Int. J. Ped. Hematol. Oncol. 1, 437-447.
38. SCANDELLA, D., MATTINGLY, M., and PRESCOTT, R.A. (1993). Recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2. Blood 82, 1767-1775.
39. SMITH, T.A.G., MEHAFFERY, M.G., KAYDA, D.B., SAUNDERS, J.M., YEI, S., TRAPNELL, B.C., McCLELLAND, A., and KALEKO, M. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genet. 5, 397-402.
40. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vector. Nature Med. 2, 545-550.
41. VERMA, I.M., and NIKUNJ, S. (1997). Gene therapy - promises, problems and prospects. Nature (London) 389, 239-242.
42. WORGALL, S., WOLFF, G., FALCK-PEDERSEN, E., and CRYSTAL, R.G. (1996). Non-immune mechanisms dominate elimination of adenovirus vectors following in vivo administration. Pediatr. Pulmonol. 20, 419.
43. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GÖNCZÖL, X., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
44. YANG, Y., TRINCHIERI, G., and WILSON, J.M. (1995a). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1, 890-893.
45. YANG, Y., LI, Q., ERTL, H., and WILSON, J.M. (1995b). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J. Virol. 69, 2004-2015.
46. YANG, Y., JOOSS, K., SU, Q., ERTL, H.C.J., and WILSON, J.M. (1996a). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in-vivo. Gene Ther. 3, 137-144.
47. YANG, Y., GREENOUGH, K., and WILSON, J.M. (1996b). Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3, 412-420.